Ibuprofen-Functionalized Alkyl α-hydroxy Methacrylate-Based Polymers.

Novel alkyl α-hydroxymethacrylate-based prodrugs are prepared to improve bioavailability, decrease toxicity, and control drug release. First, an ibuprofen (IBU)-functionalized methacrylate (TBMA-IBU) is synthesized from the reaction of tert-butyl α-bromomethacrylate with IBU. The free radical homopolymerization and copolymerization with poly(ethylene glycol) methyl ether methacrylate (Mn = 300), cleavage of tert-butyl ester groups of the homopolymer and a copolymer with trifluoroacetic acid (TFA) gave new polymer prodrugs (p-TBMA-IBU, p-TBMA-IBU-co-PEGMA, p-MA-IBU, and p-MA-IBU-co-PEGMA), with IBU linked through ester bonds on the side chain. The release studies showed extended-release of IBU (20-60% in 15 d), which can be triggered under the stimulation of lipase. The in vitro studies indicate that the representative polymers are effective in relieving inflammatory responses in RAW264.7 macrophage cells without any cytotoxicity. These results suggest that the synthesized polymers with controllable functionality can be promising IBU prodrugs.